InvestorsHub Logo
Followers 51
Posts 4564
Boards Moderated 0
Alias Born 12/14/2009

Re: None

Sunday, 02/19/2017 3:08:17 AM

Sunday, February 19, 2017 3:08:17 AM

Post# of 18784
APRIL is the month:If P3 for Zoptrex shows succesfull results in April, share price of AEZS will be ++$20/share afterwarts (before FDA decision). This because of the Adam Feuerstein biotech oncology rule: The F-R Rule is still 100% accurate predicting failure for oncology phase III studies undertaken by companies with market caps< $300M. https://www.google.be/amp/s/www.thestreet.com/amp/story/12696926/1/the-feuerstein-ratain-rule-update-still-perfect-predicting-small-cap-cancer-drug-failure.html?client=safari
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AEZS News